scholarly journals Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective

2021 ◽  
Author(s):  
Nan Qiao ◽  
Ralph Insinga ◽  
Thomas Burke ◽  
Gilberto Lopes
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cost Minimization ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
Payer Perspective ◽  
First Line Treatment

Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal

2009 ◽  
Vol 10 (11) ◽  
pp. 1031-1032 ◽  
Author(s):  
Panagiota Vrouchou ◽  
Prashanth Kandaswamy ◽  
Elisabeth George ◽  
David Barnett
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document